Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Evofem Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$2.76M. For fiscal 2025 it was $3.37M. The highest annual figure on record is $3.37M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.37M | – |
| FY2024 | Dec 31, 2024 | -$7.68M | – |
| FY2023 | Dec 31, 2023 | -$17.85M | – |
| FY2022 | Dec 31, 2022 | -$84.12M | – |
| FY2021 | Dec 31, 2021 | -$166.80M | – |
| FY2020 | Dec 31, 2020 | -$103.62M | – |
| FY2019 | Dec 31, 2019 | -$52.74M | – |
| FY2018 | Dec 31, 2018 | -$77.64M | – |
| FY2017 | Dec 31, 2017 | -$35.69M | – |
| FY2016 | Dec 31, 2016 | -$12.04M | – |
| FY2015 | Dec 31, 2015 | -$42.05M | – |
| FY2014 | Dec 31, 2014 | -$9.59M | – |
| FY2013 | Dec 31, 2013 | -$14.42M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.49M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.57M | -1497.2% |
| Q4 FY2025 | Dec 31, 2025 | $3.35M | – |
| Q3 FY2025 | Sep 30, 2025 | $951.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.25M | – |
| Q1 FY2025 | Mar 31, 2025 | $327.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.44M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.84M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.72M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.93M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.42M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$41.14M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.87M | – |
| Q4 FY2020 | Dec 31, 2020 | -$35.85M | – |
| Q3 FY2020 | Sep 30, 2020 | -$26.16M | – |
| Q2 FY2020 | Jun 30, 2020 | -$22.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.24M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.87M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.30M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.94M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.63M | – |
| Q4 FY2018 | Dec 31, 2018 | -$14.98M | – |
| Q3 FY2018 | Sep 30, 2018 | -$18.43M | – |
| Q2 FY2018 | Jun 30, 2018 | -$23.24M | – |
| Q1 FY2018 | Mar 31, 2018 | -$20.99M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.35M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.07M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.36M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.91M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.98M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.87M | – |
| Q2 FY2016 | Jun 30, 2016 | -$2.52M | – |
See a number that looks wrong?